hVIVO plc
("hVIVO", the "Company" or the
"Group")
Capital Markets Event and
Trading Update on 17 July
hVIVO plc (AIM & Euronext:
HVO), a fast growing specialist contract
research organisation (CRO) and world leader in testing infectious
and respiratory disease products using human challenge clinical
trials, announces that it will be holding a
Capital Markets Event at the Company's new state-of-the-art
facility in Canary Wharf for analysts, institutional investors, and
media on Wednesday 17 July 2024 at 10.00 am - 12.30 pm
(BST). The Company also expects to announce a trading update
for the six months ended 30 June 2024 on the same day.
The event will focus on the
capabilities of the world's largest human challenge trial unit and
how it will enhance and broaden hVIVO's services, as
well as covering the Group's trading update. CEO
Yamin 'Mo' Khan will chair the event that will include speakers
from across the Group, as well as a fireside chat with a number of
external speakers discussing the utility of human challenge trials.
There will also be an opportunity for attendees to take part in
Q&A sessions with the speakers and to tour the laboratory and
challenge trial unit.
Analysts, institutional investors and
media are welcome to attend the in-person event. Due to
restrictions on numbers, it will not be possible for all interested
parties to attend in-person, however, a live webcast will be
available on the Company's website for retail investors and others
to view the presentations here.
To register your interest for the
event or webcast, please contact Walbrook PR on +44 20 7933 8780 or
email hvivo@walbrookpr.com.
A recording of the presentation will be made available on the
Company's website after the event.
For further information please
contact:
|
hVIVO plc
|
+44 (0) 20
7756 1300
|
|
Yamin 'Mo' Khan, Chief Executive Officer
Stephen Pinkerton, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
|
+44 (0) 20
7220 0500
|
|
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward
|
|
|
|
|
|
Peel Hunt LLP (Joint Broker)
|
+44 (0)20
7418 8900
|
|
James Steel, Dr Christopher Golden
|
|
|
|
|
|
Davy
(Euronext Growth Adviser and Joint Broker)
|
+353 (0) 1
679 6363
|
|
Anthony Farrell, Niall
Gilchrist
|
|
|
|
|
|
Walbrook PR (Financial PR
& IR)
Stephanie
Cuthbert / Phillip Marriage /
Louis Ashe-Jepson
|
+44 (0) 20
7933 8780 or hvivo@walbrookpr.com
+44 (0)
7796 794 663 / +44 (0) 7867 984 082 /
+44 (0) 7747 515 393
|
|
|
|
|
| |
Notes to
Editors
About
hVIVO
hVIVO plc
(ticker: HVO) (formerly Open Orphan plc) is a fast growing
specialist contract research organisation (CRO) and the world
leader in testing infectious and respiratory disease vaccines and
therapeutics using human challenge clinical trials. The Group
provides end-to-end early clinical development services to its
large, established and growing repeat client base, which includes
four of the top 10 largest global biopharma companies.
The Group's fast-growing services business
includes a unique portfolio of 11 human challenge models, with a
number of new models under development, to test a broad range of
infectious and respiratory disease products. The Group has world
class challenge agent manufacturing capabilities, specialist drug
development and clinical consultancy services via its Venn Life
Sciences brand, and a lab offering via its hLAB brand, which
includes virology, immunology biomarker and molecular testing. The
Group offers additional clinical field trial services such as
patient recruitment and clinical trial site services.
hVIVO runs challenge trials in London - its
new state-of-the-art facilities in Canary Wharf opened in 2024 and
is the world's largest commercial human challenge trial unit, with
highly specialised on-site virology and immunology laboratories,
and an outpatient unit. To recruit volunteers / patients for its
studies, the Group leverages its unique clinical trial recruitment
capability via its FluCamp volunteer screening
facilities in London and Manchester.